Universal Flu Vaccine Enters Human Trials

The ritual of the annual flu shot is a familiar, if slightly annoying, part of modern healthcare. Every year, scientists predict which strains will be dominant, manufacturers rush to produce doses, and the public lines up for protection that typically ranges from 40% to 60% effectiveness. The National Institutes of Health (NIH) is working to change that dynamic forever. A Phase 1 clinical trial has officially begun for a universal influenza vaccine candidate designed to provide long-lasting protection against a wide array of flu strains.

The Science of the "Conserved Stem"

To understand why this new vaccine is different, you must understand the anatomy of the influenza virus. Under a microscope, the flu virus looks like a ball covered in spikes. These spikes are a protein called hemagglutinin (HA).

Scientists often compare the HA protein to a mushroom:

• The Head (The Cap): This is the top part of the protein. It is the part current seasonal flu vaccines target. The problem is that the “head” mutates constantly. This is why you need a new shot every year; the virus changes its appearance to evade your immune system.
• The Stem (The Stalk): This is the base of the protein that attaches to the virus body. Unlike the head, the stem does not mutate often. It remains “conserved” or consistent across many different strains of the flu.

The experimental vaccine currently in trials targets this conserved stem. If the immune system can be trained to recognize and attack the stem, the virus cannot hide even if the head mutates. This approach could theoretically protect against seasonal drift as well as potential pandemic strains that cross over from animals.

Inside the NIH Clinical Trial

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. It is being conducted at the Duke University Vaccine and Trials Unit in Durham, North Carolina.

The specific vaccine candidate is known as H1ssF-3928 mRNA-LNP.

How the Candidate Works

This experimental vaccine utilizes the messenger RNA (mRNA) platform, the same technology used in the Pfizer-BioNTech and Moderna COVID-19 vaccines. The vaccine delivers a specific instruction to the body’s cells to produce a stabilized version of the influenza stem.

The body then produces antibodies against this stem. Researchers at the NIAID Vaccine Research Center (VRC) developed this specific protein design. Their early testing in animals showed that the vaccine induced protective immune responses against a variety of Group 1 influenza viruses.

Trial Structure and Goals

This is a Phase 1 trial, meaning the primary focus is safety and dosing rather than proving efficacy across a massive population.

• Participants: The study plans to enroll up to 50 healthy volunteers aged 18 to 49.
• Groups: Participants are divided into groups to test different dosage levels (likely 50 micrograms) and to compare the experimental vaccine against current seasonal quadrivalent flu shots.
• Timeline: While the injections happen quickly, researchers will follow the volunteers for up to a year to monitor long-term safety and antibody levels.

Why Current Flu Shots Fall Short

The current manufacturing process for flu vaccines is a race against time. The World Health Organization (WHO) meets twice a year to review surveillance data and decide which four strains (two Influenza A and two Influenza B) should go into the vaccine.

This process has two major flaws:

1. Prediction Error: If the virus mutates between the time the selection is made in February and the flu season starts in October, the vaccine is a “mismatch.” In severe mismatch years, effectiveness can drop below 20%.
2. Egg Adaptations: Most flu vaccines are grown in chicken eggs. Sometimes, the virus adapts to grow better in the egg, changing its structure enough that the resulting vaccine doesn’t perfectly match the wild virus circulating in humans.

The mRNA universal vaccine bypasses the egg production process entirely, allowing for a purer match to the genetic sequence designed by the scientists.

The Road to Approval

While the start of human trials is a major milestone, a commercially available universal flu shot is still several years away.

If Phase 1 results at Duke University show the vaccine is safe and generates the expected immune response, the NIH will move to Phase 2 trials with hundreds of volunteers. Phase 3, which involves thousands of participants and determines exactly how well the vaccine prevents illness in the real world, would follow.

However, the implications are massive. A successful universal vaccine could eliminate the need for annual vaccinations. Instead, people might only need a booster every five or ten years, similar to a tetanus shot. Furthermore, it acts as a global security policy against future pandemics. If a new, deadly strain of bird flu or swine flu jumps to humans, a population with immunity to the “conserved stem” would likely have a baseline of protection against severe disease and death.

Frequently Asked Questions

What is the specific name of the vaccine being tested? The candidate currently in this specific NIH trial is identified as H1ssF-3928 mRNA-LNP. It uses lipid nanoparticles to deliver mRNA instructions for the hemagglutinin stem.

Will this vaccine protect against all types of flu? The goal is broad protection. While early iterations might focus on Group 1 Influenza A viruses (which include common H1N1 strains), the ultimate scientific objective is a vaccine that covers both Influenza A and B groups.

How is this different from the COVID-19 vaccine? It uses the same delivery vehicle (mRNA inside a lipid shell), but the “payload” is different. Instead of coding for the SARS-CoV-2 spike protein, it codes for the stem of the influenza hemagglutinin protein.

When will I be able to get this vaccine? It is currently in Phase 1 trials. Standard vaccine development takes several years to pass through Phase 2 and Phase 3 safety and efficacy hurdles. If successful, it could be available to the public later this decade.

Is the NIH the only group working on this? No. Several pharmaceutical companies and academic institutions are pursuing universal flu vaccines using different technologies, including ferritin nanoparticles and different mRNA formulations. However, the NIAID trial represents a significant government-backed push toward this technology.